Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Natrunix

Monoclonal antibody · Antagonist of interleukin-1 alpha (IL1A) · developed by XBiotech

Phase 2 Most advanced trial (none active)

XBIT Developer

1 Registered trials

What is Natrunix?

Natrunix is a human monoclonal antibody that neutralizes interleukin-1α (IL-1α), a key mediator of interleukin-1 inflammation. It is being studied in rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: interleukin-1 alpha (IL1A)
Mechanism: Antagonist of interleukin-1 alpha (IL1A)
Pathways: interleukin-1 inflammation
Therapy area: Immunology
Developer: XBiotech, Inc. (XBIT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05363891	Phase 2	Rheumatoid Arthritis	Completed	XBIT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis

Other drugs acting on IL1A

Hutrukin Phase 1 Lutikizumab Phase 2 Vilamakitug Phase 2

More from XBiotech

514G3 Phase 1/2 Hutrukin Phase 1 Vilamakitug Phase 2

Sources

ClinicalTrials.gov NCT05363891

Updated Oct 3, 2026. Something wrong or missing? Report it on the XBIT page.

Follow XBIT, the company behind Natrunix

See XBIT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XBIT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z